Telo Genomics Corp (TELO) NPV
Telo Genomics Corp. is a Canada-based biotech company. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for numerous diseases that display genomic instability. Its lead application, Telo-MM is being developed to provide information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. The Company's TeloView software consists of two parts, analytical software and a corresponding report designed for clinical decision making. TeloView utilizes the three-dimensional analysis of approximately six parameters generated from the telomeres of a single cell. Its TeloView software generates a report for the clinician that contains information, including the stage of a given disease, its rate of progression and how it responds to therapy. Its solutions include liquid biopsies and related technologies in oncology and neurological diseases.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.